Eagle Pharmaceuticals Inc. (EGRX) 12.05 $EGRX
Eagle Pharmaceuticals' Exclusive Licensor Granted U.S. Patent for Dantrolene in the Treatment of Heat Stroke
Business Wire - Tue Apr 01, 8:06AM CDT
Eagle Pharmaceuticals, Inc. ("Eagle"

(NASDAQ:EGRX) announced today that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle's dantrolene sodium for injectable suspension ("dantrolene"

. The patent issued today expires in 2023. Eagle's dantrolene formulation for the treatment of Exertional Heat Stroke (EHS) was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012.
Update on Eagle Pharma's Ryanodex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 11:00AM CDT
The FDA will review the NDA on Ryanodex on a priority basis.
NDA for Eagle Pharmaceuticals' Orphan Drug Ryanodex(R) for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted
Business Wire - Thu Mar 20, 7:00AM CDT
Eagle Pharmaceuticals, Inc. ("EAGLE"

(NASDAQ:EGRX) announced today that the United States Food and Drug Administration has accepted the company's New Drug Application for Ryanodex(R) (dantrolene) and granted a priority review classification. The PDUFA date is July 22, 2014.
Talmer, Eagle Pharma, Flexion up in trading debuts
AP - Wed Feb 12, 10:17AM CST
NEW YORK (AP) — Three companies, a bank and two drug developers, making their market debuts are trading higher on Wednesday on the Nasdaq.
Eagle Pharmaceuticals Announces Pricing of Initial Public Offering
Business Wire - Tue Feb 11, 10:39PM CST
EAGLE PHARMACEUTICALS, INC. ("EAGLE"

(NASDAQ:EGRX) announced today the pricing of its initial public offering of 3,350,000 shares of common stock at a price to the public of $15.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "EGRX" on February 12, 2014. Eagle is offering all of the shares of common stock. Eagle has also granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.